Compass Pathways

CMPS

Market cap $706M

Compass Pathways plc experienced an >80% rally since my last 'Hold' rating. CMPS has benefited from positive phase 3 trial results and positive political developments since my last article. Recent approval of JNJ's Spravato as a standalone product in treatment of TRD offers significant piggybacking opportunity for Compass.

COMPASS Pathways plc (CMPS) Discusses Clinical Trial Plans for PTSD and Commercial Preparations for Treatment-Resistant Depression Transcript

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company's clinica.

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration, with Radial Health, Inc., a growing national network of interventional psychiatry practices leveraging technology and operations expertise to optimize models of care delivery. This collaboration will further help to inform the development of scalable delivery.

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a webinar to discuss the company's commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD) from 10:00-11:30 am ET on January 7, 2026. The discussion will include KOL and industry leaders' perspect.

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following December investor conferences: 8th Annual Evercore Healthcare Conference – Coral Gables, FL: Fireside chat at 10:00am ET on December 2, 2025 Piper Sandler 37th Annual Healthcare Conference – New York, NY: Fireside chat at 1:30pm ET on December 3, 2.

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Stifel 2025 Healthcare Conference in New York, NY at 10:40 am ET on Tuesday, November 11, 2025. A live audio webcast of these events will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be ac.

COMPASS Pathways plc ( CMPS ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - CEO & Director Teri Loxam - CFO, Principal Financial Officer & Principal Accounting Officer Lori Englebert - Chief Commercial Officer Steve Levine - Chief Patient Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Judah Frommer - Morgan Stanley, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Chi Wen Chin - TD Cowen, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Presentation Operator Good morning, ladies and gentlemen, and thank you for standing by.

Drug developer Compass Pathways said on Tuesday it is pulling forward the expected launch timing of its experimental psilocybin-based depression therapy by 9 to 12 months.

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business. “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 mon.